Hazardous Alcohol Use and Its Effect on Direct-Acting Antiviral Therapy Initiation among People with Active Injection Drug Use and Current Hepatitis C Infection

Viruses Pub Date : 2024-09-05 DOI:10.3390/v16091416
Hamidreza Karimi-Sari, Gregory M. Lucas, Katie Zook, Brian Weir, Miles Landry, Susan G. Sherman, Kathleen R. Page, Oluwaseun Falade-Nwulia
{"title":"Hazardous Alcohol Use and Its Effect on Direct-Acting Antiviral Therapy Initiation among People with Active Injection Drug Use and Current Hepatitis C Infection","authors":"Hamidreza Karimi-Sari, Gregory M. Lucas, Katie Zook, Brian Weir, Miles Landry, Susan G. Sherman, Kathleen R. Page, Oluwaseun Falade-Nwulia","doi":"10.3390/v16091416","DOIUrl":null,"url":null,"abstract":"Background: Hepatitis C virus (HCV) infection and hazardous alcohol use are both preventable causes of morbidity and mortality among people who inject drugs (PWID). In the general population, hazardous alcohol is associated with a reduced likelihood of HCV treatment initiation. Less is known about the prevalence and impact of hazardous alcohol use on direct-acting antiviral (DAA) therapy initiation among PWID with active injection drug use. Methods: PWID were recruited via street outreach in Baltimore, Maryland, between 2018 and 2019 and were enrolled in a study cohort. Participants completed a study survey and underwent HCV testing. Self-reported DAA therapy initiation was evaluated at follow-up visits every six months. Hazardous alcohol use was determined based on an AUDIT-C score of ≥4 for men or ≥3 for women. Data were analyzed using multivariable logistic regression with generalized estimating equations. Results: Of the 720 PWID recruited, 291 had detectable HCV RNA, and only 134 were aware of their HCV infection. The mean (±standard deviation) age of those that were aware of their infection was 48.7 (±10.3) years, with a slight majority (53.0%) being male and predominantly African American (64.9%). The majority (80/134, 59.7%) met criteria for hazardous alcohol use. Only 16 (11.9%) PWID reported DAA therapy initiation within six months, and 20 (14.9%) reported it within 12 months of follow-up. Hazardous alcohol use (aOR = 1.23, 95% CI = 0.43–3.53) was not associated with DAA treatment initiation. Conclusions: There was a high prevalence of hazardous alcohol use, low rates of oral DAA therapy initiation, and no association between self-reported hazardous alcohol use and initiation of oral DAA therapy in our sample of PWID that were aware of their chronic HCV infection. Strategies to increase HCV treatment uptake in PWID with active drug use are urgently needed and should integrate alcohol and drug use evaluation and care.","PeriodicalId":501326,"journal":{"name":"Viruses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/v16091416","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hepatitis C virus (HCV) infection and hazardous alcohol use are both preventable causes of morbidity and mortality among people who inject drugs (PWID). In the general population, hazardous alcohol is associated with a reduced likelihood of HCV treatment initiation. Less is known about the prevalence and impact of hazardous alcohol use on direct-acting antiviral (DAA) therapy initiation among PWID with active injection drug use. Methods: PWID were recruited via street outreach in Baltimore, Maryland, between 2018 and 2019 and were enrolled in a study cohort. Participants completed a study survey and underwent HCV testing. Self-reported DAA therapy initiation was evaluated at follow-up visits every six months. Hazardous alcohol use was determined based on an AUDIT-C score of ≥4 for men or ≥3 for women. Data were analyzed using multivariable logistic regression with generalized estimating equations. Results: Of the 720 PWID recruited, 291 had detectable HCV RNA, and only 134 were aware of their HCV infection. The mean (±standard deviation) age of those that were aware of their infection was 48.7 (±10.3) years, with a slight majority (53.0%) being male and predominantly African American (64.9%). The majority (80/134, 59.7%) met criteria for hazardous alcohol use. Only 16 (11.9%) PWID reported DAA therapy initiation within six months, and 20 (14.9%) reported it within 12 months of follow-up. Hazardous alcohol use (aOR = 1.23, 95% CI = 0.43–3.53) was not associated with DAA treatment initiation. Conclusions: There was a high prevalence of hazardous alcohol use, low rates of oral DAA therapy initiation, and no association between self-reported hazardous alcohol use and initiation of oral DAA therapy in our sample of PWID that were aware of their chronic HCV infection. Strategies to increase HCV treatment uptake in PWID with active drug use are urgently needed and should integrate alcohol and drug use evaluation and care.
危险饮酒及其对注射毒品使用活跃和当前丙型肝炎感染者开始直接作用抗病毒疗法的影响
背景:丙型肝炎病毒(HCV)感染和酗酒都是注射吸毒者(PWID)发病和死亡的可预防原因。在普通人群中,酗酒与开始接受丙型肝炎病毒(HCV)治疗的可能性降低有关。而在积极使用注射毒品的 PWID 中,危险饮酒的发生率及其对启动直接作用抗病毒疗法(DAA)的影响却鲜为人知。方法:2018年至2019年期间,在马里兰州巴尔的摩市通过街头宣传招募了一些PWID,并将其纳入研究队列。参与者完成了一项研究调查并接受了 HCV 检测。在每六个月一次的随访中对自我报告的 DAA 治疗启动情况进行评估。男性 AUDIT-C 评分≥4 分,女性 AUDIT-C 评分≥3 分,即为危险饮酒。数据采用多变量逻辑回归和广义估计方程进行分析。结果:在招募的 720 名吸毒者中,291 人检测到了 HCV RNA,只有 134 人知道自己感染了 HCV。已知感染者的平均年龄(± 标准差)为 48.7 (±10.3) 岁,男性略占多数(53.0%),以非洲裔美国人为主(64.9%)。大多数人(80/134,59.7%)符合危险饮酒的标准。只有 16 名(11.9%)PWID 报告在 6 个月内开始接受 DAA 治疗,20 名(14.9%)报告在随访的 12 个月内开始接受 DAA 治疗。危险饮酒(aOR = 1.23,95% CI = 0.43-3.53)与开始接受 DAA 治疗无关。结论在我们已知其慢性 HCV 感染的吸毒者样本中,危险饮酒的发生率很高,口服 DAA 治疗的启动率很低,而且自我报告的危险饮酒与口服 DAA 治疗的启动之间没有关联。我们亟需制定策略,提高有吸毒行为的吸毒者接受 HCV 治疗的比例,并应将酗酒和吸毒评估与护理结合起来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信